Dr. Mary L. Disis
Mary L. Disis, MD, FASCO, chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Planning Committee, commented on the importance of holding the Symposium at this time.
The Symposium will provide attendees a forum in which to discuss the range of new discoveries in immuno-oncology.
“There are so many new and exciting agents coming into the clinic for immunotherapy, from monoclonal antibodies targeting the next generation of checkpoint inhibitor proteins to oncolytic virus therapy, CAR T-cell therapy, and new approaches to cancer vaccines,” Dr. Disis said. “Having one meeting encapsulate the breadth of the field is truly exciting.”
The Symposium will shed light on the ways in which immune-based therapies have advanced beyond melanoma and will explore the clinical issues that arise from application within different disease sites.
Symposium attendees can expect “Immunology 101” sessions, as well as presentations on novel trial designs and high-throughput technologies used to better identify predictive biomarkers.
“There will be something for everyone, whether you are coming from outside of the field, a junior investigator coming into the field, or a clinician wanting to learn more about how to best treat your patients,” Dr. Disis said.